In neurodegenerative conditions with cognitive impairment, specifically in AD, [18F]FDG PET is viewed as a marker of neurodegeneration (N) and progression, and currently included—along with hippocampal volume measured with MRI—in the A/T/N classification scheme with amyloid-ß (A) and tau (T). Here, MAPT is linked to Cognitive impairment.